Sigilon Therapeutics Performance
| SGTXDelisted Stock | USD 21.11 0.33 1.54% |
The entity has a beta of 11.11, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sigilon Therapeutics will likely underperform. Sigilon Therapeutics right now has a risk of 0.0%. Please validate Sigilon Therapeutics treynor ratio, as well as the relationship between the expected short fall and day median price , to decide if Sigilon Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sigilon Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Sigilon Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 108.5 M |
Sigilon |
Sigilon Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,111 in Sigilon Therapeutics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Sigilon Therapeutics or generate 0.0% return on investment over 90 days. Sigilon Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Sigilon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sigilon Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sigilon Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sigilon Therapeutics, and traders can use it to determine the average amount a Sigilon Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SGTX |
Based on monthly moving average Sigilon Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sigilon Therapeutics by adding Sigilon Therapeutics to a well-diversified portfolio.
Sigilon Therapeutics Fundamentals Growth
Sigilon Stock prices reflect investors' perceptions of the future prospects and financial health of Sigilon Therapeutics, and Sigilon Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sigilon Stock performance.
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (1.71) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 28.99 M | |||
| Shares Outstanding | 2.5 M | |||
| Price To Book | 0.25 X | |||
| Price To Sales | 0.87 X | |||
| Revenue | 12.94 M | |||
| EBITDA | (41.27 M) | |||
| Cash And Equivalents | 88.21 M | |||
| Cash Per Share | 2.72 X | |||
| Total Debt | 28.06 M | |||
| Debt To Equity | 0.61 % | |||
| Book Value Per Share | 10.97 X | |||
| Cash Flow From Operations | (51.47 M) | |||
| Earnings Per Share | (14.83) X | |||
| Total Asset | 87.28 M | |||
| Retained Earnings | (256.8 M) | |||
About Sigilon Therapeutics Performance
Evaluating Sigilon Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sigilon Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sigilon Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.Things to note about Sigilon Therapeutics performance evaluation
Checking the ongoing alerts about Sigilon Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sigilon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sigilon Therapeutics is not yet fully synchronised with the market data | |
| Sigilon Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.94 M. Net Loss for the year was (43.56 M) with loss before overhead, payroll, taxes, and interest of (24.69 M). | |
| Sigilon Therapeutics currently holds about 88.21 M in cash with (51.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.72. |
- Analyzing Sigilon Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sigilon Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sigilon Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sigilon Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sigilon Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sigilon Therapeutics' stock. These opinions can provide insight into Sigilon Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |